Despite advancements in cognitive-behavior therapies, no single pharmacological therapy has successfully treated the disruptive-compulsive behaviors of Autism Spectrum Disorders (ASD), which include hand-flapping, tantrums, and self-injurious behaviors (Fido and Al-Saad 2008). Among the pharmacological agents examined to reduce disruptive-compulsive behaviors, atypical antipsychotics, including olanzapine, showed the most promise (Fido and Al-Saad 2008; Malek-Ahmadi and Simonds 1998; Malone et al. 2001). Specifically, ASD children prescribed olanzapine showed significant reductions in irritability, hyperactivity, and lethargy (Fido and Al-Saad 2008; Malek-Ahmadi and Simonds 1998; Malone et al. 2001). Unlike typical antipsychotic medications, atypical antipsychotic medications block postsynaptic dopamine and serotonin receptors and have a lower risk of extrapyramidal symptoms, such as dyskinesias, among children and adolescents (Malone et al. 2001)....
References and Reading
- Malone, R. P., Cater, J., Sheikh, R. M., Choudhury, M. S., & Delaney, M. A. (2001). Olanzapine versus haloperidol in children with autistic disorder: An open pilot study. Journal of the American Academy of Child & Adolescent Psychiatry, 40(8), 887–894. https://doi.org/10.1097/00004583-200108000-00009.CrossRefGoogle Scholar